# A Rare Case of Subglottic Malignant Lymphoma Requiring Emergency Tracheostomy

**Authors:** Teru Kamogashira, Kazuka Arimoto, Megumi Kishimoto, Kazuki Miyano, Shinichi Ishimoto

PMC · DOI: 10.7759/cureus.94893 · Cureus · 2025-10-18

## TL;DR

A rare case of subglottic lymphoma in a 61-year-old woman required emergency tracheostomy and was successfully treated with chemotherapy.

## Contribution

Presents a rare clinical case of subglottic lymphoma managed through emergency tracheostomy and long-term successful treatment.

## Key findings

- Emergency tracheostomy was necessary due to progressive airway obstruction from a subglottic lymphoma.
- Histological analysis identified a low-grade B-cell lymphoma, likely CD5-positive MALT lymphoma.
- Chemotherapy with bendamustine and rituximab led to a seven-year complete response.

## Abstract

Primary malignant lymphoma originating in the laryngeal tissue is rare. A 61-year-old woman was admitted to our hospital with hoarseness and mild dyspnea for three weeks. The fiberscopic examination revealed slight edema around the vocal cords. Despite four weeks of inhaled steroid therapy, progressive worsening of the subglottic lesion led to increasing airway obstruction, and due to diagnostic uncertainty and the risk to the airway, emergent tracheostomy was performed. Fiberscopic findings through the tracheostomy stoma revealed multiple tumors around the anterior tracheal wall and a submucosal bulge around the posterior tracheal wall in the subglottic area, so biopsies from both areas were performed. Histological examination revealed a low-grade B-cell lymphoma (probable CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma, unclassifiable). As a further biopsy would have required general anesthesia and might still have yielded insufficient tissue for definitive subclassification, treatment was initiated for an unclassifiable low-grade B-cell lymphoma, with a plan to perform a repeat biopsy at recurrence for diagnostic confirmation. The patient subsequently received chemotherapy with bendamustine and rituximab and has sustained a complete response for seven years.

## Linked entities

- **Chemicals:** bendamustine (PubChem CID 65628)
- **Diseases:** lymphoma (MONDO:0003659), MALT lymphoma (MONDO:0007650)

## Full-text entities

- **Genes:** CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}
- **Diseases:** Primary malignant lymphoma (MESH:D008223), lesion (MESH:D009059), mucosa-associated lymphoid tissue (MALT) lymphoma (MESH:D018442), airway obstruction (MESH:D000402), hoarseness (MESH:D006685), grade B-cell lymphoma (MESH:D016393), dyspnea (MESH:D004417), tumors (MESH:D009369), low (MESH:D009800), edema (MESH:D004487)
- **Chemicals:** steroid (MESH:D013256), rituximab (MESH:D000069283), bendamustine (MESH:D000069461)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12624241/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12624241/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12624241/full.md

---
Source: https://tomesphere.com/paper/PMC12624241